【摘要】 目的 :观察评价善得定对重症急性胰腺炎 (SAP)的临床疗效。方法 :SAPⅠ级 32例 ,SAPⅡ级 2 9例 ,各随机分为普通治疗组 (N组 )和联用善得定组 (S组 ) ,观察比较各N、S两组临床疗效。结果 :两级SAP患者 ,S组Binder合并症积分下降较快 (P <0 .0 0 1 ) ,住院时间较短 (P <0 .0 1 )。在SAPⅠ级 ,S组后遗症发生率较低 (P <0 .0 5 )。在SAPⅡ级 ,S组ICU监护时间较短 (P <0 .0 5 ) ,转手术率较低 (P <0 .0 5 )。两级S组均未发现与善得定确切相关的严重不良反应。结论 :SAP患者在综合救治的基础上早期使用善得定能显著改善临床过程 ,缩短疗程 ,改善预后 ,近期疗效确切。更多还原

【Abstract】 Objective:To observed and evaluated the effects of Sandostatin on Severe Acute Pancreatilis(SAP) in the clinic study. Methods:32 cases of grade Ⅰ SAP and 29 cases of grade Ⅱ SAP were divided respectively into group N,in which patients were treated with normal method,and group S,in which patients were treated with Sandostatin except normal method.The treatment effects of every group were observed.Results:At both grades,Binders value of complications decreased faster in group S than that in group N( P <0.001),and the duration of hospitalization was shorter in group S( P <0.01).At grade Ⅰ,morbidity of seguela was lower in group S( P <0.05).Besides,in group S of grade Ⅱ,a shorter ICU and a lower operation rate were discovered.Seriour infavorable reactions correlated with sandostatin were not observed in both two groups.Conclusion:On the basis of synthetic treatment,early usage of Sandostatin can shorten the course and improve the prognosis of SAP.更多还原